Clinical trials: Cell- and Tissue-Based Therapy
Cell- and Tissue-Based Therapy
Amnion Bilayer and Stem Cell Combination Therapy on Thin Endometrium Infertile Patients
Severe infections or trauma to the endometrial lining causes permanent scars that disrupt the menstrual cycle and lead to conceive failure.
- Trial name
- NCT04676269
- Testing
- Amnion only, Amnion - endometrium cells, Amnion - amnion epithelial cells
- Where
- Indonesia
- Volunteers
- 40 people
- Sponsor
- Universitas Indonesia
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
WHIM, Warts
Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM
Background: Warts, hypogammaglobulinemia, infections and myelokathexis syndrome (WHIMs) is a rare disorder that affects the immune system. People with WHIMs can have severe infections all over their body.
- Conditions
- WHIM, Warts, Hypogammaglobulinemia, Immunodeficiency
- Trial name
- NCT07775313
- Testing
- Busulfan, Palifermin, Plerixafor
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Esthesioneuroblastoma, Olfactory
Esthesioneuroblastoma: Outcomes After Treatment
The purpose of this study is to collect and organize data into a repository to gather relevant information for future research from patients diagnosed with a rare malignant sinonasal cancer called esthesioneuroblastoma (ENB) and…
- Trial name
- ENB (NCT02580136)
- Where
- United States
- Sponsor
- Ricardo L. Carrau, MD
Spinal Cord Injuries (SCI), Spinal Cord Injury
Guttmann NeuroRecovery - Viability, Safety, and Efficacy of Intrathecal Wharton's Jelly Mesenchymal Stem Cells and Transcutaneous Spinal Cord Stimulation in Chronic Spinal Cord Injury Rehabilitation
This clinical trial primarily aims to evaluate the safety and feasibility of a combined therapeutic approach for chronic spinal cord injury (SCI).
- Conditions
- Spinal Cord Injuries (SCI), Spinal Cord Injury, Traumatic Spinal Cord Injuries, Spinal Cord Disease
- Trial name
- GNR-SCI-01 (NCT06981338)
- Testing
- Allogeneic Wharton's jelly mesenchymal stem cells (WJ-MSCs)
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Institut Guttmann
Sarcoma, Desmoplastic Small Round Cell Tumor (DSRCT)
Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor
This study adds irinotecan, temozolomide and bevacizumab to the chemotherapy regimen currently used to treat Desmoplastic small round cell tumor (DSRCT).
- Trial name
- NCT01189643
- Testing
- irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Osteogenesis Imperfecta
Mesenchymal Stem Cell Based Therapy for the Treatment of Osteogenesis Imperfecta
The purpose of this study is to determine the safety and effectiveness of five infusions of characterized HLA-identical MSC in non immunosuppressed children with Osteogenesis Imperfecta (OI).
- Trial name
- TERCELOI (NCT02172885)
- Testing
- Mesenchymal Stem Cells
- Where
- 2 sites in Spain
- Volunteers
- 2 people
- Sponsor
- Hospital de Cruces
Glioma
PERMA-Based Intervention on Negative Emotions, Adherence, and Complications in Postoperative Glioma Patients
The goal of this clinical trial is to evaluate whether a PERMA-based integrated psychological intervention can reduce negative emotions, enhance treatment adherence, and decrease the risk of complications in postoperative glioma…
- Trial name
- Glioma (NCT06713395)
- Testing
- The control group received standard postoperative care, PERMA
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Yang Huang
Glioblastoma Multiforme
Dendritic Cell Cancer Vaccine for High-grade Glioma
A randomised, open-label, 2-arm, multi-centre, phase II clinical study with one group receiving standard therapy with Temozolomide, radiotherapy, and Trivax; and a control group receiving standard therapy with Temozolomide and…
- Trial name
- GBM-Vax (NCT01213407)
- Testing
- Trivax, Temozolomide, Surgery, Radiotherapy, Temozolomide, Surgery, Radiotherapy
- Where
- 8 sites in Austria
- Volunteers
- 87 people
- Sponsor
- Activartis Biotech
Recurrent Childhood Medulloblastoma
GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment
This phase I trial is studying the side effects and best dose of GDC-0449 in treating young patients with medulloblastoma that is recurrent or did not respond to previous treatment.
- Trial name
- NCT00822458
- Testing
- vismodegib, laboratory biomarker analysis, pharmacological study
- Where
- 9 sites in United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma
MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma
This study will evaluate the safety and preliminary efficacy of Multi-Antigen Stimulated Cell Therapy-I Injection (MASCT-I) in combination with Apatinib and/or Camrelizumab in patients with advanced bone and soft-tissue sarcoma.
- Trial name
- NCT04074564
- Testing
- MASCT-I, Camrelizumab,Apatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- HRYZ Biotech Co.
Rheumatoid Arthritis
Cell Phone Based Automated Monitoring of Patients With Early Rheumatoid Arthritis
The purpose of this study is to determine whether automated remote monitoring of patients with early rheumatoid arthritis by the SandRA software and short message service of cell phones increases patient compliance and helps to…
- Trial name
- SandRA (NCT02424877)
- Testing
- SandRA
- Where
- 2 sites in Finland
- Volunteers
- 165 people
- Sponsor
- Medcare Oy
Brain Tumor, Neurofibromatoses
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
In this study, the main goal is to implement and evaluate a novel, evidence-based psycho-educative program for children in oncological care. Patients are provided with booklets tailored to each specific stage of their treatment.
- Conditions
- Brain Tumor, Neurofibromatoses, Sarcoma, Leukemia
- Trial name
- NCT04474678
- Testing
- "My Logbook! - I know my way around!"
- Where
- 22 sites in Austria, Germany and 2 more
- Volunteers
- 240 people
- Sponsor
- Medical University of Vienna
Sarcoma
Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors
RATIONALE: Giving chemotherapy drugs, such as busulfan, melphalan, and thiotepa, before a donor stem cell transplant helps stop the growth of tumor cells and prepares the patient's bone marrow for the stem cells.
- Trial name
- NCT00357396
- Testing
- graft versus host disease prophylaxis/therapy, busulfan, melphalan
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diabetic Foot Ulcers, Venous Stasis Ulcer
Cellular and Tissue Based Therapy Registry
The goal of the Cellular and Tissue Based Therapy Registry (CTPR) for Wounds is to provide real world patient data from electronic health records submitted to meet Stage 2 Meaningful Use in order to understand the value of these…
- Conditions
- Diabetic Foot Ulcers, Venous Stasis Ulcer, Pressure Ulcer, Chronic Non Healing Wound
- Trial name
- CTPR (NCT02322554)
- Testing
- Cellular and tissue based products
- Where
- United States
- Volunteers
- 50,000 people
- Sponsor
- U.S. Wound Registry
Ganglioneuroblastoma, Localized Resectable Neuroblastoma
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor may not need treatment until it progresses.
- Conditions
- Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Neuroblastoma
- Trial name
- NCT02176967
- Testing
- Biopsy Procedure, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 222 sites in United States, Australia and 4 more
- Volunteers
- 391 people
- Sponsor
- Children's Oncology Group